An entirely new category of medicine is emerging, and a new wave of digital therapeutics start-ups is joining the effort to bring meaning and definition to this new industry.
What started out six years ago as a local ‘passion project’ for Bayer to collaborate with Berlin’s digital health scene has grown into a truly global programme.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh